SCHEMBL17159692

SCHEMBL17159692

[CH2]N1C(=O)C(C)(C)Oc2ccc(Nc3nc(Nc4cc(OC)c(OC)c(OC)c4)ncc3F)nc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 11/20 0.73
▸ PTK2 Q05397 4/20 0.73
▸ PLK4 O00444 2/20 0.73
▸ AURKA O14965 2/20 0.73
▸ STK16 O75716 2/20 0.73
▸ RET P07949 2/20 0.73
▸ FLT3 P36888 2/20 0.73
▸ MAPK8 P45983 2/20 0.73
▸ MAPK9 P45984 2/20 0.73
▸ MST1R Q04912 2/20 0.73
▸ TNK1 Q13470 2/20 0.73
▸ IKBKE Q14164 2/20 0.73
▸ MAP3K11 Q16584 2/20 0.73
▸ ADCK1 Q86TW2 2/20 0.73
▸ PIP4K2C Q8TBX8 2/20 0.73
▸ NEK9 Q8TD19 2/20 0.73
▸ AURKB Q96GD4 2/20 0.73
▸ IRAK3 Q9Y616 2/20 0.73
▸ LATS1 O95835 1/20 0.73
▸ BRDT Q58F21 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2627480 0.92 SYK (0.76) SYKPTK2PLK4AURKASTK16
SCHEMBL16682499 0.90 SYK (0.80) SYKPTK2PLK4AURKASTK16
SCHEMBL14837744 0.89 SYK (0.72) SYKPTK2PLK4AURKASTK16
SCHEMBL2627484 0.89 SYK (0.84) SYKPTK2PLK4AURKASTK16
SCHEMBL4108129 0.89 SYK (0.81) SYKPTK2PLK4AURKASTK16
SCHEMBL13451897 0.87 SYK (0.84) SYKPTK2PLK4AURKASTK16
SCHEMBL20490119 0.87 SYK (0.70) SYKPTK2PLK4AURKASTK16
SCHEMBL11937322 0.87 SYK (0.70) SYKPTK2PLK4AURKASTK16
SCHEMBL20006821 0.86 SYK (0.82) SYKPTK2PLK4AURKASTK16
SCHEMBL16820329 0.86 SYK (0.89) SYKPTK2PLK4AURKASTK16

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3738084-A1 G1T38 SUPERIOR DOSAGE REGIMES G1 Therapeutics, Inc. (US) 2020-11-18 — — EP disclosed
US-20150290235-A1 USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS AB SCIENCE (FR) 2015-10-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290235-A1 USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS DCK, ADK, DTYMK SYK 225/4885PTK2 1019/4885PLK4 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback